Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | From epigenetic mechanisms to cancer therapeutics

Stephen Nimer • 4 Dec 2015
ASH 2015
General

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center, New York, NY, reviews promising epigenetic targets in cancer and explains that combining epigenetic therapies with immunotherapies may improve outcomes for patients.

More from Stephen Nimer

1:18
Update on immunotherapy in MDS
Stephen Nimer • 5 Mar 2020
0:53
How to improve transplant outcomes in MDS?
Stephen Nimer • 5 Mar 2020
1:02
Stephen Nimer: MDS highlights
Stephen Nimer • 5 Mar 2020
1:19
The promise of precision medicine in MDS
Stephen Nimer • 5 Mar 2020

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals